Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AC-170 0.24% in Healthy Adults
NCT02173249Phase 1Completed
- Sponsor
- Aciex Therapeutics
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetirizine in allergic conjunctivitis (AC), sponsored by Aciex Therapeutics. Primary endpoints: Maximum Plasma Concentration at 1 week, Time to Maximum Plasma Concentration at 1 week and 2 more. Started Jun 2014; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02173249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173249.